Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Autologous Anti-EGFR/Anti-IL13Ra2 CAR T-cells, Autologous Anti-EGFR/IL13Ra2 CAR T Cells, Autologous Anti-EGFR/IL13Ra2 CAR-T Cells, CART-EGFR-IL13Ra2 Cells

Pipeline

Phase 1: 1

Top Sponsors

City of Hope Medical Center1

Indications

Recurrent Astrocytoma, IDH-Mutant, Grade 41
Recurrent Glioblastoma, IDH-Wildtype1
Cancer1

Duarte, California1 trial

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

City of Hope Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.